Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KDM5C | P41229 | 3/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28425942 | 0.87 | HPGD (0.57) | CYP2D6CYP2C19HPGDEPHX2MMP1 | |
| SCHEMBL8049135 | 0.84 | CYP2D6 (0.48) | CYP2D6CYP2C19HPGDEPHX2FOLH1 | |
| SCHEMBL7426956 | 0.82 | CYP2D6 (0.50) | CYP2D6CYP2C19HPGDEPHX2PHF8 | |
| SCHEMBL13311531 | 0.82 | CYP2D6 (0.50) | CYP2D6CYP2C19HPGDEPHX2ALDH1A1 | |
| SCHEMBL17313809 | 0.81 | CYP2D6 (0.61) | CYP2D6CYP2C19HPGDEPHX2ALDH1A1 | |
| SCHEMBL22310461 | 0.81 | PHF8 (0.42) | HPGDEPHX2PHF8KDM2AKDM4E | |
| SCHEMBL799421 | 0.81 | PHF8 (0.42) | CYP2D6CYP2C19HPGDPHF8KDM2A | |
| SCHEMBL6537134 | 0.80 | LMNA (0.52) | CYP2D6CYP2C19HPGDEPHX2KDM4E | |
| SCHEMBL13669328 | 0.80 | CYP2D6 (0.48) | CYP2D6CYP2C19HPGDEPHX2ALDH1A1 | |
| SCHEMBL743998 | 0.80 | CYP2D6 (0.48) | CYP2D6CYP2C19HPGDEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111423396-B | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2023-01-06 | — | — | CN | disclosed |
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
| CN-111423396-A | sEH inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2020-07-17 | — | — | CN | disclosed |
| US-8580545-B2 | Biodegradable linkers for molecular therapies | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130243862-A1 | PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2013-09-19 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7635734-B2 | Photochemical activation of surfaces for attaching biomaterial | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2009-12-22 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070293927-A1 | Gene and Cell Delivery Self Expanding Polymer Stents | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2007-12-20 | — | — | US | disclosed |
| EP-0815084-B1 | LACTAM-CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEASE | PROCTER & GAMBLE (US) | 2003-08-27 | — | — | EP | disclosed |
| US-5672598-A | MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | CYP2D6 465/4885CYP2C19 712/4885HPGD 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.